Thera-SAbDab

MODOTUXIMAB

>   Structural Summary
TherapeuticModotuximab
TargetEGFR
Heavy ChainQVQLQQPGAELVEPGGSVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGEINPSSGRNNYNEKFKSKATLTVDKSSSTAYMQFSSLTSEDSAVYYCVRYYGYDEAMDYWGQGTSVTVSS
Light ChainDIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Phase-II
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2012
INN Year Recommended2014
Companies InvolvedSymphogen%3BMerck
Conditions Approvedna
Conditions ActiveColorectal cancer%3BGlioma%3BNon-small cell lung cancer
Conditions DiscontinuedHead and neck cancer%3BOesophageal cancer
NotesModotuximab is the new name for Zatuximab %28PL110%29

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy